PURPOSE: Primary Sjögren's syndrome (SjS) is an autoimmune disorder characterized by lymphocytic infiltration of the salivary and lacrimal glands, B-cell clonal expansions and an increased risk of lymphoma. In order to understand the role of B cells in this disorder, the antibody repertoire and B-cell maturation were studied in a mouse model of SjS called B6.Aec1/2. METHODS: B6.Aec1/2 serum was analyzed for antibodies by ELISA and immunoprecipitation, B-cell development by flow cytometry, and antibody gene rearrangements by CDR3 spectratyping and quantitative PCR. In order to test the functional consequences of the observed defects, B6.Aec1/2 mice were crossed with anti-dsDNA antibody heavy chain knock-in mice (B6.56R). RESULTS: B6.Aec1/2 mice exhibit B-cell clonal expansions, have altered serum immunoglobulin levels and spontaneously produce multireactive autoantibodies. B6.Aec1/2 mice also have decreased numbers of bone marrow pre-B cells and decreased frequencies of kappa light chain gene deletion. These findings suggest that B6.Aec1/2 mice have a defective early B-cell tolerance checkpoint. B6.56R.Aec1/2 mice unexpectedly had lower anti-dsDNA antibody levels than B6.56R mice and less salivary gland infiltration than B6.Aec1/2 mice. CONCLUSIONS: These data suggest that the early tolerance checkpoint defect in B6.Aec1/2 mice is not sufficient to promulgate disease in mice with pre-formed autoantibodies, such as B6.56R. Rather, B6.Aec1/2 mice may require a diverse B-cell repertoire for efficient T-B-cell collaboration and disease propagation. These findings imply that therapies aimed at reducing B-cell diversity or T-B interactions may be helpful in treating SjS.
PURPOSE: Primary Sjögren's syndrome (SjS) is an autoimmune disorder characterized by lymphocytic infiltration of the salivary and lacrimal glands, B-cell clonal expansions and an increased risk of lymphoma. In order to understand the role of B cells in this disorder, the antibody repertoire and B-cell maturation were studied in a mouse model of SjS called B6.Aec1/2. METHODS: B6.Aec1/2 serum was analyzed for antibodies by ELISA and immunoprecipitation, B-cell development by flow cytometry, and antibody gene rearrangements by CDR3 spectratyping and quantitative PCR. In order to test the functional consequences of the observed defects, B6.Aec1/2 mice were crossed with anti-dsDNA antibody heavy chain knock-in mice (B6.56R). RESULTS: B6.Aec1/2 mice exhibit B-cell clonal expansions, have altered serum immunoglobulin levels and spontaneously produce multireactive autoantibodies. B6.Aec1/2 mice also have decreased numbers of bone marrow pre-B cells and decreased frequencies of kappa light chain gene deletion. These findings suggest that B6.Aec1/2 mice have a defective early B-cell tolerance checkpoint. B6.56R.Aec1/2 mice unexpectedly had lower anti-dsDNA antibody levels than B6.56R mice and less salivary gland infiltration than B6.Aec1/2 mice. CONCLUSIONS: These data suggest that the early tolerance checkpoint defect in B6.Aec1/2 mice is not sufficient to promulgate disease in mice with pre-formed autoantibodies, such as B6.56R. Rather, B6.Aec1/2 mice may require a diverse B-cell repertoire for efficient T-B-cell collaboration and disease propagation. These findings imply that therapies aimed at reducing B-cell diversity or T-B interactions may be helpful in treating SjS.
Authors: Ricardo C Ferreira; Qiang Pan-Hammarström; Robert R Graham; Vesela Gateva; Gumersindo Fontán; Annette T Lee; Ward Ortmann; Elena Urcelay; Miguel Fernández-Arquero; Concepción Núñez; Gudmundur Jorgensen; Björn R Ludviksson; Sinikka Koskinen; Katri Haimila; Hilary F Clark; Lars Klareskog; Peter K Gregersen; Timothy W Behrens; Lennart Hammarström Journal: Nat Genet Date: 2010-08-08 Impact factor: 38.330
Authors: S S Kassan; T L Thomas; H M Moutsopoulos; R Hoover; R P Kimberly; D R Budman; J Costa; J L Decker; T M Chused Journal: Ann Intern Med Date: 1978-12 Impact factor: 25.391
Authors: Kevin M Nickerson; Sean R Christensen; Jaime L Cullen; Wenzhao Meng; Eline T Luning Prak; Mark J Shlomchik Journal: J Immunol Date: 2013-01-07 Impact factor: 5.422
Authors: Manuel Sáez Moya; Rebeca Gutiérrez-Cózar; Joan Puñet-Ortiz; María Luisa Rodríguez de la Concepción; Julià Blanco; Jorge Carrillo; Pablo Engel Journal: Front Immunol Date: 2021-04-23 Impact factor: 7.561
Authors: Cintia S de Paiva; Claudia M Trujillo-Vargas; Laura Schaefer; Zhiyuan Yu; Robert A Britton; Stephen C Pflugfelder Journal: Front Immunol Date: 2021-07-19 Impact factor: 7.561